

Successful Drug Discovery

Successful Drug Discovery

Volume 4

Edited by
János Fischer,
Christian Klein,
Wayne E. Childers

WILEY-VCH

Editors

János Fischer
Richter Co., Plc.
Gyömrői út 19/21
1103 Budapest
Hungary

Christian Klein
Roche Innovation Center Zürich
Cancer Immunotherapy Division
Wagistrasse 10
8952 Schlieren
Switzerland

Wayne E. Childers
Temple University School of Pharmacy
Moulder Ctr. for Drug Discovery Res.
3307 N Broad Street
Philadelphia, PA 19140
United States

Cover

Supported by the international Union of Pure
and Applied Chemistry (IUPAC)
Chemistry and Human Health Division
PO Box 13757
Research Triangle Park, NC 2770-3757
USA

■ All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek
The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-34468-0
ePDF ISBN: 978-3-527-81470-1
ePub ISBN: 978-3-527-81471-8
oBook ISBN: 978-3-527-81469-5

Typesetting SPi Global, Chennai, India
Printing and Binding

Printed on acid-free paper

10 9 8 7 6 5 4 3 2 1

Contents

Advisory Board Members *xi*

Preface *xiii*

Part I General Aspects 1

- 1 Trends in Peptide Therapeutics 3**
Florence M. Brunel, Fa Liu, and John P. Mayer
- 1.1 Introduction 3
- 1.2 Peptides in Metabolic Diseases 4
 - 1.2.1 Insulins 4
 - 1.2.2 Glucagon-like Peptide-1 6
 - 1.2.3 Glucagon 8
 - 1.2.4 Combination Therapies 8
- 1.3 Peptide Antibiotics 9
 - 1.3.1 Non-ribosomally Synthesized 9
 - 1.3.2 Ribosomally Synthesized 11
- 1.4 Peptides in Cancer 12
 - 1.4.1 Luteinizing Hormone Releasing Hormone 12
 - 1.4.2 Somatostatin 13
 - 1.4.3 Peptide–Drug Conjugates 14
 - 1.4.4 Cancer Vaccines 15
- 1.5 Peptides in Bone Diseases 16
 - 1.5.1 Calcitonin 16
 - 1.5.2 Parathyroid Hormone (PTH) (1–34) and (1–84) 17
 - 1.5.3 Parathyroid Hormone Related Protein 18
 - 1.5.4 Incretin Peptides 19
 - 1.5.5 Bone Morphogenic Protein-Derived Peptides 19
- 1.6 Peptides in Gastrointestinal Diseases 19
 - 1.6.1 Glucagon-like Peptide-2 19
 - 1.6.2 Guanylate Cyclase-C Agonists 20
- 1.7 Emerging Trends in Peptide Drug Discovery 22
 - 1.7.1 Cell-Penetrating Peptides 22
 - 1.7.2 Macrocyclic Peptides 23
- 1.8 Summary 23

	Acknowledgment	24
	List of Abbreviations	24
	References	25
	Biographies	34
2	Physicochemical Parameters of Recently Approved Oral Drugs	35
	<i>Andreas Ritzén and Laurent David</i>	
2.1	Introduction	35
2.2	FDA-Approved Drugs 2007–2017	36
2.2.1	Conclusions	40
2.3	Polar Surface Area in bRo5 Territory	42
2.3.1	Finding Chameleons with Molecular Dynamics	44
2.3.2	Conclusions	48
2.3.3	Methods	49
	List of Abbreviations	50
	References	51
	Biographies	52
	Part II Drug Class Studies	55
3	Antibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer	57
	<i>Caroline Denevault-Sabourin, Francesca Bryden, Marie-Claude Viaud-Massuard, and Nicolas Joubert</i>	
3.1	Introduction	57
3.2	First Generation ADCs	58
3.2.1	Molecular Design	58
3.2.2	Mechanism of Action	60
3.2.3	Therapeutic Applications	60
3.2.4	Adverse Effects	60
3.3	Second Generation ADCs	62
3.3.1	Molecular Design	62
3.3.2	Mechanism of Action	63
3.3.3	Therapeutic Applications	67
3.3.4	Adverse Effects	67
3.4	Toward Next Generation ADCs	68
3.4.1	Site-Specific ADCs	69
3.4.2	New Formats of Immunoconjugates	70
3.4.3	ADC with New Payloads	74
3.5	Summary	76
	List of Abbreviations	76
	References	77
	Biographies	81

4	Dopamine D₂ Partial Agonists – Discovery, Evolution, and Therapeutic Potential	83
	<i>Marlene Jacobson, Wayne Childers, and Magid Abou-Gharbia</i>	
4.1	Introduction	83
4.2	Dopamine and Dopamine Receptors	83
4.2.1	Functional Selectivity and Biased Ligand Signaling	86
4.3	Schizophrenia and Earlier Antipsychotic Agents	86
4.4	Dopamine Partial Agonism	88
4.5	D ₂ Partial Agonists	89
4.5.1	Dopamine-like Scaffolds – The “Classical” Pharmacophore	89
4.5.2	Non-dopamine-like Scaffolds – The “Nonclassical” Pharmacophore	91
4.5.3	Compounds Related to Bifeprunox	92
4.5.4	Methylaminochroman Scaffold – Aplindore	94
4.5.5	D ₂ Partial Agonist Drug Discovery in the Wake of the Marketed Drugs	95
4.5.5.1	D ₂ Partial Agonists Discovered Using Traditional D ₂ Functional Screening	96
4.5.5.2	Bivalent Ligands	98
4.5.5.3	β-Arrestin-Biased D ₂ Partial Agonists	98
4.5.5.4	G-protein-Biased D ₂ Partial Agonists	99
4.5.6	Arylpiperazines and the Discovery of Aripiprazole and Brexpiprazole	101
4.5.7	The Road Leading to Cariprazine	102
4.6	Marketed D ₂ Partial Agonist Antipsychotics	103
4.6.1	Aripiprazole (Abilify [®])	104
4.6.1.1	History	105
4.6.1.2	Synthesis	105
4.6.1.3	Drug Substance	105
4.6.1.4	Pharmacology	105
4.6.1.5	Functional Selectivity and Biased Ligand Signaling	107
4.6.1.6	Pharmacokinetics and Metabolism	107
4.6.1.7	Clinical Data	107
4.6.2	Brexpiprazole (Rexulti [®])	108
4.6.2.1	History	108
4.6.2.2	Synthesis	108
4.6.2.3	Drug Substance	109
4.6.2.4	Pharmacology	109
4.6.2.5	Functional Selectivity and Biased Ligand Signaling	110
4.6.2.6	Pharmacokinetics and Metabolism	110
4.6.2.7	Clinical Data	110
4.6.3	Cariprazine (Vraylar [®])	111
4.6.3.1	History	111
4.6.3.2	Synthesis	112

- 4.6.3.3 Drug Substance 112
- 4.6.3.4 Pharmacology 112
- 4.6.3.5 Functional Selectivity and Biased Ligand Signaling 113
- 4.6.3.6 Pharmacokinetics 113
- 4.6.3.7 Clinical Data 114
- 4.7 Conclusions 115
- List of Abbreviations 116
- References 117
- Biographies 129

Part III Case Studies 131

- 5 Discovery of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease 133**
Amos Baruch and Derek Maclean
 - 5.1 Introduction 133
 - 5.2 Compound Design and Structure–Activity Relationships 135
 - 5.2.1 Optimization of the Cationic Charge 135
 - 5.2.2 Alanine Scan of dCR₆ 136
 - 5.2.3 Double Alanine Scan of dCR₆ 138
 - 5.2.4 SAR of Alanine Residues in Ac-carrarar-NH₂ and Ac-crrrarar-NH₂ 138
 - 5.2.5 Importance of the Thiol Residue 140
 - 5.2.6 Thiol Conjugates – Selection of Etelcalcetide 140
 - 5.3 Preclinical Studies 141
 - 5.4 Mechanism of Action of Etelcalcetide 144
 - 5.5 Clinical Studies 145
 - 5.6 Summary 149
 - Acknowledgments 149
 - List of Abbreviations 149
 - References 150
 - Biographies 153
- 6 Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor Targeting VEGF and FGF Receptors 155**
Akihiko Tsuruoka, Yasuhiro Funahashi, Junji Matsui, and Tomohiro Matsushima
 - 6.1 Introduction 155
 - 6.2 Recent Progress in the Development of Molecular Targeted Anticancer Agents 155
 - 6.3 Tumor Angiogenesis 156
 - 6.4 Development of Resistance to VEGF-Targeting Drugs 156
 - 6.5 Discovery of Lenvatinib, a Drug Targeting VEGFR and FGFR 157
 - 6.6 Inhibition of Kinase Activity by Lenvatinib and Discovery of the Novel Type V Kinase-Binding Mode 158

- 6.7 Antitumor Effects of Lenvatinib in Human Thyroid Cancer Cell Lines 161
- 6.8 Antitumor Effects of Lenvatinib in Human Renal Cell Cancer Cell Lines and Its Mechanism of Action 162
- 6.9 Conclusions and Perspectives 162
 - List of Abbreviations 163
 - References 164
 - Biographies 167

- 7 Ocrelizumab: A New Generation of anti-CD20 mAb for Treatment of Multiple Sclerosis 169**
Andrew C. Chan, Paul Brunetta, and Peter Chin
 - 7.1 Introduction: B Cells Play Critical Roles in Immunity 169
 - 7.2 Role of B Cells in Autoimmunity 172
 - 7.3 CD20-Targeting Therapeutic Antibodies 173
 - 7.4 Rituximab: the First Anti-CD20 mAb Experience in Autoimmunity 176
 - 7.5 Effects of Rituximab on Antibodies and Autoantibodies 178
 - 7.6 Rituximab in AAV and Other Autoimmune Disorders 178
 - 7.7 Beginnings of Ocrelizumab 179
 - 7.8 Multiple Sclerosis 180
 - 7.9 Multiple Sclerosis Disease Pathogenesis 181
 - 7.10 Rituximab: The First Anti-CD20 mAb Experience in Multiple Sclerosis 183
 - 7.10.1 HERMES Junior 183
 - 7.10.2 HERMES 183
 - 7.10.3 OLYMPUS 184
 - 7.11 Ocrelizumab in Multiple Sclerosis 184
 - 7.11.1 OPERA 185
 - 7.11.2 ORATORIO 186
 - 7.12 The Conundrum of B Cells in Multiple Sclerosis 187
 - 7.13 Final Comments 187
 - List of Abbreviations 188
 - Acknowledgments 189
 - References 189
 - Biographies 198

- 8 The Story of Rucaparib (Rubraca) 201**
Bernard T. Golding
 - 8.1 Introduction 201
 - 8.2 Benzoxazole-/Benzimidazole-carboxamides and Quinazolinones 205
 - 8.3 The Road to Rucaparib/Rubraca 212
 - 8.4 The Emergence of Single-Agent Therapy 216
 - 8.5 Clinical Studies 217

8.6	Conclusion	218
	Acknowledgments	218
	References	219
	Biography	223
9	Discovery and Development of Venetoclax, a Selective Antagonist of BCL-2	225
	<i>Wayne J. Fairbrother, Joel D. Levenson, Deepak Sampath, and Andrew J. Souers</i>	
9.1	Introduction	225
9.2	Discovery of Venetoclax – Structure-Based Design	227
9.3	Preclinical Studies	232
9.3.1	Mechanism of Action	232
9.3.2	Predictive Biomarkers of Venetoclax Sensitivity	233
9.3.3	Efficacy of Venetoclax as Monotherapy and in Combination with Targeted Agents or Chemotherapeutics	234
9.4	Clinical Studies	236
	List of Abbreviations	238
	References	239
	Biographies	244
	Index	247

Advisory Board Members

Magid Abou-Gharbia

(Temple University, USA)

Jagath R. Junutula

(Cellerant Therapeutics, Inc., USA)

Kazumi Kondo

(Otsuka, Japan)

John A. Lowe

(JL3Pharma LLC, USA)

Gerd Schnorrenberg

(Boehringer Ingelheim, Germany)

Preface

The fourth volume of *Successful Drug Discovery* continues to follow the structure of the previous volumes, consisting of three parts: General Aspects, Drug Class Studies, and Case Studies. The book series focuses on new discoveries of small-molecule drugs and biologics.

The editors thank the advisory board members: Magid Abou-Gharbia (Temple University, USA), Jagath R. Junutula (Cellerant Therapeutics, Inc., USA), Kazumi Kondo (Otsuka), John A. Lowe (JL3Pharma LLC, USA), and Gerd Schnorrenberg (Boehringer Ingelheim, Germany), and the following reviewers who helped both the authors and the editors: Jonathan Baell, Gabriele Costantino, György Domány, John M. Beals, Stephen Hauser, Jagath R. Junutula, Béla Kiss, Paul Leeson, Gábor Mező, Tomi Sawyer, Malcolm Stevens, Michael Wagner, Peng Wu. Special thanks are due to Juergen Stohner for his review from the viewpoints of the IUPAC Interdivisional Committee on Terminology, Nomenclature and Symbols (ICTNS).

Part I: General Aspects

John P. Mayer and coworkers give a comprehensive survey on the recent progress in peptide therapeutics. Remarkable achievements in various therapeutic fields and several orally administered peptides are summarized in this chapter.

Andreas Ritzén and coworker investigate the physicochemical parameters of recently approved drugs. A significant fraction of non-CNS oral drugs violate two or more of the Lipinski parameters.

Part II: Drug Class Studies

Nicolas Joubert and coworkers give an overview on antibody–drug conjugates in cancer-targeted chemotherapy. Over the last decade, they have been improved by the choice of better drugs, linkers, and mAb targets.

Wayne E. Childers and coworkers evaluate three decades in the discovery of D₂ partial agonist drugs. Progress has been made in treating the negative and cognitive symptoms of schizophrenia.

Part III: Case Studies

Derek Maclean and coworker report on the discovery of *etelcalcetide*, which affords a suitable therapy for hemodialysis patients with secondary hyperparathyroidism.

Akihiko Tsuruoka and coworkers describe how *lenvatinib mesylate* was discovered to give a new drug for the treatment of differentiated thyroid cancer.

Andrew C. Chan and coworkers describe the discovery and development of *ocrelizumab*, which represents a new generation of anti-CD20 mAb for the treatment of multiple sclerosis.

Bernard T. Golding has prepared a chapter on the discovery and development of *rucaparib*, a new PARP-1 inhibitor anticancer drug for the treatment of ovarian cancer. It also represents an example of a good cooperation of academia and industry.

Wayne J. Fairbrother and coworkers describe how *venetoclax*, a selective antagonist of B cell lymphoma 2 (Bcl-2), was discovered for the treatment of leukemia.

The editor and authors thank Wiley-VCH, and personally Dr. Frank Weinreich for the excellent cooperation.

Budapest
Philadelphia
Zurich
8 November 2018

János Fischer
Wayne E. Childers
Christian Klein

Part I

General Aspects

1

Trends in Peptide Therapeutics

Florence M. Brunel¹, Fa Liu², and John P. Mayer³

¹ Novo-Nordisk Research Center, 5225 Exploration Dr., Indianapolis, IN, 46241, USA

² Novo-Nordisk Research Center, 530 Fairview Avenue North, Seattle, WA, 98109, USA

³ University of Colorado, MCD Biology, 1945 Colorado Avenue, Boulder, CO, 80309, USA

1.1 Introduction

The growing importance of peptide drugs within the pharmacopoeia has become evident over the past several decades. Among the factors that have contributed to this trend is the recognition that peptide ligands regulate a multitude of physiological pathways and are often suitable for therapeutic applications, in either their native or modified form. In addition, certain attributes that are unique to peptides, such as their high selectivity, potency, and lack of toxicity, have ultimately become appreciated. The alternative means of drugging peptide receptors through target-directed screening or rational design of orally available small molecules have, with few exceptions, proved unproductive. Mimicking the activity of a peptide agonist is highly challenging, particularly in the case of Class II G-protein-coupled receptor (GPCR) targets. Successful examples have typically involved receptor antagonists such as neurokinin, angiotensin, endothelin, and orexin. These lessons have increasingly led drug discovery scientists to consider peptides as legitimate drug candidates, rather than leads or proof-of-concept models for small-molecule programs. Peptide medicinal chemists have also had to confront and overcome shortcomings such as rapid metabolism, clearance, production costs, and limited alternative delivery options. In the present chapter, we highlight the role of peptides in therapeutic areas such as metabolic disease, where peptides have been well established, as well as in areas where their impact has been minor, but now rapidly expanding. We also emphasize examples where time-extension strategies and alternative delivery routes have helped establish and strengthen the position of peptide drugs in competitive markets. Finally, we explore two novel trends in peptide drug discovery, macrocyclic and cell-penetrating peptides, both of which may expand future opportunities for peptide therapeutics.

1.2 Peptides in Metabolic Diseases

The global epidemic of type 2 diabetes and obesity continues unabated, impacting quality of life, life expectancy, and economic well-being. Health-care organizations have devoted enormous resources toward the treatment of metabolic diseases, often dramatically improving patient outcomes [1]. Perhaps more than in any other therapeutic area, peptides have had a unique and indispensable role in treating type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) as well as obesity. This section will provide an overview of approved insulin, GLP-1 (glucagon-like peptide-1), and glucagon peptide drugs as well as those in late-stage clinical development.

1.2.1 Insulins

Insulin, which was discovered by Banting and Best in 1921, became commercially available only one year after its discovery (Figure 1.1) [2]. In spite of its miraculous potential, the short duration of action of early insulin preparations (four to six hours) required multiple daily injections and prompted the search for longer acting formulations. The first of these, insulin neutral protamine Hagedorn (NPH), developed in the 1940s, consisted of an insulin suspension complexed with protamine, a cationic protein isolated from fish sperm. The slow disassociation of the NPH complex delayed absorption from the injection site, prolonging insulin action to a range of 12 to 18 hours [3]. Insulin Lente, introduced in the 1950s, involved a neutral pH suspension of insulin formulated with excess zinc, which extended the duration of action to 24 hours and beyond [3]. Between the 1920s and the early 1980s, commercial insulin production relied on extraction of pancreatic glands from cows and pigs. The advent of biotechnology enabled the production of rDNA-derived human insulin in the early 1980s in sufficient quantity to satisfy the needs of the diabetic population, gradually




Figure 1.1 Sequences of human, porcine, bovine, and the commercially key insulin analogs.